-
Mashup Score: 21
Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if patients with an On-X mechanical aortic…
Source: Artivion Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy - 2 year(s) ago
Abstract Background Subclinical obstructive valve thrombosis after transcatheter aortic valve replacement (TAVR) is of uncertain frequency and clinical impact. Objectives The aim of this study was …
Categories: Expert Picks, Latest HeadlinesTweet-
The #ATLANTIS-4D-CT RCT sub-study shows #apixaban reduces subclinical obstructive valve thrombosis in patients undergoing #TAVR without an indication for anticoagulation. https://t.co/FULeq7fycu #JACCINT #CardioTwitter @ActionCoeur https://t.co/1TlwAt79aI
-
-
Mashup Score: 3
FootnotesCirculation is available at www.ahajournals.org/journal/circThis manuscript was sent to Paul Gurbel, Guest Editor, for review by expert referees, editorial decision, and final disposition.For Sources of Funding and Disclosures, see page 960.Correspondence to: Sana M. Al-Khatib, MD, MHS, Duke Clinical Research Institute, 300 Morgan St, Durham, NC 27701. Email…
Source: CirculationCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#ResearchLetter: In the ARISTOTLE trial, a 2-3-day interruption of #apixaban before invasive procedures assoc with the most favorable efficacy and safety (incl low risk of stroke and major bleeding) @SanaAlkhatib9 #AHAJournals https://t.co/t7VaVa4H8t https://t.co/zc9IF2Dp36
-
-
Mashup Score: 2Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study - 2 year(s) ago
AbstractAims. The aim of this study was to compare the risk of stroke or systemic embolism (SE) and major bleeding in patients with atrial fibrillation (AF) usi
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Comparison of #dabigatran #rivaroxaban, and #apixaban : a nationwide cohort study #AF https://t.co/degbjOMH3H
-
-
Mashup Score: 4Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation: - 2 year(s) ago
Abstract Background Direct-acting oral anticoagulants are first-line agents for prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF), but data are limited for the oldest pat…
Source: JACC: AdvancesCategories: Expert Picks, Latest HeadlinesTweet-
Older women had higher than expected peak apixaban concentrations, & 2.5 mg twice daily produced lower concentrations than standard dosing. The impact of apixaban concentrations on outcomes needs evaluation. https://t.co/7cDQtW2mKl #JACCAdvances #Cardiology #Geriatrics #Apixaban https://t.co/fab2agVLbk
-
-
Mashup Score: 4
This retrospective cohort study uses data from fee-for-service Medicare (2009-2017) and from 2 commercial health insurance (2004-2018) databases to compare extended prescription dispenses for apixaban, rivaroxaban, and warfarin after hospitalization for venous thromboembolism.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#Apixaban, c/w #warfarin, beyond 90d was signif assoc w lower rate of hospitalization for recurrent #VTE, but no signif difference in risk of hospitalization for major bleed;no significant differences for comparisons of apixa vs riva and riva vs warfarin. https://t.co/6tQQRqVMyX
-
-
Mashup Score: 2Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation - 2 year(s) ago
To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF) by…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
#MA Comparing #Apixaban Versus #Rivaroxaban for Management of ... https://t.co/79vKYeV67H
-
-
Mashup Score: 9Use of Anticoagulants and Dosing Appropriateness of Apixaban for New-Onset Atrial Fibrillation Among Hemodialysis Patients - 2 year(s) ago
Atrial fibrillation (AF) affects 21% of patients with kidney failure undergoing hemodialysis (HD).1 AF is associated with 2-fold higher adjusted risk of ischemic stroke and 9 times higher adjusted mortality risk during the first 30 days after AF diagnosis in the HD population.2 In 2012 the US Food and Drug Administration (FDA) approved apixaban for AF in patients with creatinine…
Categories: Latest Headlines, NephrologyTweet-
Use of Anticoagulants and Dosing Appropriateness of Apixaban for New-Onset Atrial Fibrillation Among Hemodialysis Patients https://t.co/G9OPVAkLRZ (FREE) @MinZhuo4 @Rishidesai11 @BWHKidney #hemodialysis #Apixaban https://t.co/cmSFtCHm1c
-
-
Mashup Score: 2CVS Caremark formulary change freezes out apixaban - 2 year(s) ago
The decision doesn’t affect patients on a Medicare or Medicaid plan but hits those taking the popular anticoagulant who have select commercial insurance plans.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Patients looking to refill prescriptions for #apixaban through CVS Caremark may be in for a surprise following its decision to exclude the #DOAC from its formulary recently. https://t.co/G2KPDLRV8Q https://t.co/Mllw9GkJWw
-
-
Mashup Score: 7Apixaban may be safer for older patients with AF vs. rivaroxaban - 2 year(s) ago
Anticoagulation with rivaroxaban for patients with atrial fibrillation aged 65 years or more was associated with greater risk for major ischemic and hemorrhagic events compared with apixaban, according to data published in JAMA.“Millions of patients with atrial fibrillation, the most common sustained cardiac arrhythmia, take oral anticoagulants to prevent strokes. The most commonly
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Anticoagulation with #rivaroxaban for patients with #AFib aged 65 years or more was associated with greater risk for major ischemic and hemorrhagic events compared with #apixaban @JAMA_current @VUmedicine @healioneurology #Cardiotwitter https://t.co/10kZk9HOs8
-
The #PROACT Xa trial has been halted prematurely after it was found that #Apixaban carried a greater risk of blood clots leading to stroke when compared with #warfarin in patients with the on-X mechanical #AV https://t.co/Wqbla1Hr6y @mmamas1973 @HeartOTXHeartMD @SchakrabartiEP https://t.co/a2DbWbMbYC